University of Chicago
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Elderly
Prostate Cancer
LHRH Agonist Therapy Discontinuation
NA
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 155 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients |
| Actual Study Start Date : | 2026-06 |
| Estimated Primary Completion Date : | 2026-12 |
| Estimated Study Completion Date : | 2027-06 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 70 Years |
| Sexes Eligible for Study: | MALE |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
The University of Illinois at Chicago (UIC)
Chicago, Illinois, United States, 60607
NOT YET RECRUITING
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637